GaryRHudesMD

Oncology • Philadelphia, PA

Medical Oncologist, Philadelphia, Pennsylvania. Affiliated with multiple hospitals in the area, including Fox Chase Cancer Center and Temple University Hospital.

Join to view full profile

Are you Dr. Hudes?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 89 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
333 Cottman Ave
Fox Chase Cancer Center
Philadelphia, PA 19111
Phone+1 215-728-6900

Fax+1 215-728-3639

Summary

Dr. Gary Hudes, MD is an oncologist in Philadelphia, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania. He is affiliated with Temple University Hospital and is a Medical Oncologist at Pennsylvania. Affiliated with multiple hospitals in the area.

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1983 - 1985
Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 1982 - 1983
Graduate HospitalResidency, Internal Medicine, 1979 - 1982
State University of New York Downstate Medical Center College of MedicineClass of 1979

Certifications & Licensure

PA State Medical License 1980 - 2016

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 1999 Feb 04
Completed
Phase 2
R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy Start of enrollment: 2000 Apr 01
Completed
Phase 2
Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer Start of enrollment: 2001 Jun 01
Withdrawn
Phase 2
Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer Start of enrollment: 2003 Nov 01
Withdrawn
Phase 2
Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors Start of enrollment: 2005 Mar 01
Completed
Phase 1
Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy Start of enrollment: 2006 Nov 01
Completed
Phase 2
A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer Start of enrollment: 2008 May 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Phase II Trial of Eribulin in Patients With Metastatic Hormone Refractory Prostate Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E5805)
Mark N. Stein, Yu-Hui Chen, Michael A. Carducci, Gary R. Hudes, Pauline M. Lerma
American Journal of Clinical Oncology. 2019-04-01
2 citations
Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial.
Yu-Ning Wong, Judith Manola, Gary R. Hudes, Bruce J. Roth, Judd W. Moul
Clinical Genitourinary Cancer. 2018-04-01
27 citations
Hydroxychloroquine Destabilizes Phospho-S6 in Human Renal Carcinoma Cells.
Hyung-Ok Lee, Aladdin Mustafa, Gary R. Hudes, Warren D. Kruger
Plos One. 2015-07-02

Professional Memberships

American Society of Clinical Oncology - ASCO
Member